Quote:

---

Again, I don't understand what your concern was?

---

If you are asking seriously and not accusing me of making stuff up, I will answer.

I proved to you my first point that PsychoGenics could pull the plug on Eltoprazine at any point because Coeptis failed to raise $6M by the 4/23/2019 deadline. The settlement agreement is off unless they amend to give us more time.

What is my concern? Put yourself in the shoes of a Kitov executive or shareholder. They sign a deal with a private company to be the US face of their main drug. This private company has 4 employees but promises to raise $18 million in pre-IPO funds (announced in November, 2018) with a Hong Kong or US IPO to follow.

They haven't been able to raise the $6 million to close the Elto merger. That would give me pause as a Kitov executive or shareholder. I would have to second guess whether I wanted Coeptis to the US face of my main drug. Can they pull this off?

We hadn't heard any vote of confidence by Kitov in Coeptis since January. Then, a few days ago, we heard one. It was music to my ears. If they haven't at least thought about giving Coeptis the boot, they aren't doing their job.

Who knows what's going on behind the scenes, but I look at what I can see. Coeptis announced it would raise up to $18 million last November and couldn't raise the $6 million to close the Elto merger by late April. That's all we know.